¡Ya estamos en ! Descubre más

Establishment Labs

ESTA

Capitalización de mercado USD 1764 M

59.18 USD

-2.18

3.55%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

59.18

0.00

0%

1 día

-3.55%

5 días

-4.02%

1 mes

-16.84%

3 meses

-35.88%

6 meses

-8.26%

En lo que va del año

-14.03%

1 año

27.02%

5 años

-23.23%

10 años

139.11%

Acerca de: Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

Empleados: 1,004

Atención médica Dispositivos médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 33.3%

Neutral 55.6%

Negativo 11.1%

Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States. The approval adds 28 new sizes to the Motiva U.S. portfolio, including implants as sm.

Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform. Establishment Labs also announced the product line extensions of both Mia® and Preservé™ with new sizes and supporting tools. The announcements.

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants

Establishment Labs: Procedure Economics Strengthens The Bull Case

Establishment Labs is leveraging FDA approval and U.S. market entry to drive higher-margin growth through procedure-based offerings like Preservé. Q2 2026 results showed 31.7% revenue growth, gross margin expansion to 70.6%, and U.S. sales accounting for 89% of total growth. Preservé delivers over 2x revenue per procedure versus traditional augmentation, but long-term success hinges on repeat utilization and durable economics.

Establishment Labs: Procedure Economics Strengthens The Bull Case

Baron Discovery Fund Q2 2026 Portfolio Activity

We see a long runway for growth as Samsara expands in existing accounts and wins new logos. We believe Shake Shack is one of the most compelling growth stories in restaurants today, with a differentiated brand, improving unit economics, and an accelerating unit growth algorithm. We initiated a position in Rubrik, a subscription software company focused on automating backup, storage, and recovery of corporate data, as well as creating resilience to cyberattacks on that data.

Baron Discovery Fund Q2 2026 Portfolio Activity

Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript

Establishment Labs Q2 Earnings Call Highlights

Establishment Labs NASDAQ: ESTA reported second-quarter revenue growth of 31.7% year over year, driven by continued rapid expansion in the United States, rising adoption of its Minimally Invasive platform and improving operating leverage.

Establishment Labs Q2 Earnings Call Highlights

Zacks Investment Research

Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.57 per share a year ago.

Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates

Establishment Labs® Reports Second Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2026. Second Quarter Highlights and Outlook (Unaudited) Revenue of $67.5 million, up 31.7% from Q2 2025, and sequential growth of 12.8% from Q1 2026 $24.7 million of sales in the United States, up 26% from Q1 2.

Establishment Labs® Reports Second Quarter 2026 Financial Results

Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2026, before the market opens on Thursday, August 6, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results. To participate in the conference call, Dial: (+1) 888-396-8049 (US &amp.

Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6

The Motley Fool

A Hedge Fund Dumped Establishment Labs Shares Worth $6.6 Million. Here's a Closer Look at the Transaction.

JW Asset Management sold 90,533 shares between May 26 and May 28, 2026, generating a transaction value of ~$6.64 million at a weighted average price of around $73.31 per share. The transaction represented 3.04% of the insider's total indirect holdings, reducing indirect ownership from ~2.98 million to ~2.89 million shares.

A Hedge Fund Dumped Establishment Labs Shares Worth $6.6 Million. Here's a Closer Look at the Transaction.

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™